Protalix BioTherapeutics (NYSE:PLX) Upgraded at StockNews.com

StockNews.com upgraded shares of Protalix BioTherapeutics (NYSE:PLX) from a hold rating to a buy rating in a research report report published on Monday.

Protalix BioTherapeutics Stock Up 3.7 %

NYSE:PLX opened at $1.69 on Monday. The company has a market capitalization of $124.44 million, a PE ratio of -13.00 and a beta of 0.67. Protalix BioTherapeutics has a 52-week low of $0.82 and a 52-week high of $1.90. The stock has a fifty day simple moving average of $1.14 and a 200-day simple moving average of $1.11.

Institutional Trading of Protalix BioTherapeutics

Several large investors have recently modified their holdings of PLX. XTX Topco Ltd purchased a new stake in Protalix BioTherapeutics in the 3rd quarter valued at approximately $36,000. Cubist Systematic Strategies LLC acquired a new position in shares of Protalix BioTherapeutics in the second quarter worth $37,000. Virtu Financial LLC purchased a new stake in shares of Protalix BioTherapeutics in the third quarter valued at $44,000. AQR Capital Management LLC acquired a new stake in shares of Protalix BioTherapeutics during the second quarter valued at $67,000. Finally, Ground Swell Capital LLC purchased a new stake in Protalix BioTherapeutics during the 2nd quarter worth about $73,000. 16.53% of the stock is currently owned by institutional investors and hedge funds.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.